Overview

The Safety and The Efficacy Evaluation of ET-STEM in Patients With Frontotemporal Dementia

Status:
Not yet recruiting
Trial end date:
2026-12-31
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to evaluate the safety and the tolerability of 3 repeated doses of ET-STEM (Mesenchymal stem cells preconditioned with ethionamide) in patients with FTD.
Phase:
Phase 1
Details
Lead Sponsor:
Samsung Medical Center